Related Experiment Video

Updated: Sep 2, 2025

Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling
09:51

Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling

Published on: July 26, 2017

12.5K

The Therapeutic Potential of Targeting the Toll-like Receptor Pathway in Breast Cancer

Younes Toroghian1, Reza Khayyami2, Seyed Mahdi Hassanian3

  • 1Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.

Current Pharmaceutical Design
|August 1, 2022
PubMed

Insights

Toll-like receptor (TLR) signaling is crucial in cancer immunity and progression. Targeting TLRs offers a promising therapeutic strategy for various cancers, including breast and bladder cancer.

Area of Science:

  • Immunology
  • Oncology
  • Molecular Biology

Background:

  • Toll-like receptor (TLR) signaling is integral to immune responses.
  • TLRs are expressed in both immune and tumor cells, influencing cancer progression.
  • Dysregulation of TLRs in the tumor microenvironment presents dual roles in cancer development.

Purpose of the Study:

  • To review the mechanisms of TLR pathway involvement in cancer development and progression.
  • To highlight the therapeutic potential of targeting TLRs in malignancies.
  • To summarize current knowledge for improved cancer management strategies.

Main Methods:

  • Literature review of studies on TLR signaling in cancer.
  • Analysis of data on TLR expression in tumor cells and the tumor microenvironment.
  • Examination of therapeutic agents targeting TLR pathways.

Main Results:

  • TLR signaling is implicated in the progression of several cancers, notably breast cancer.
  • TLR activation in the tumor microenvironment can exert both anti-tumoral and pro-tumoral effects.
  • Bacillus Calmette-Guerin, a TLR2 and TLR4 agonist, is approved for bladder cancer immunotherapy.

Conclusions:

  • Targeting TLR signaling pathways represents a viable therapeutic approach for cancer treatment.
  • Understanding TLR mechanisms is essential for developing effective cancer immunotherapies.
  • Further research into TLR modulation could lead to improved management of various malignancies.
Keywords:
Bacillus Calmette-GuerinToll-like receptorsbreast cancer progressioncell proliferationdrug resistancetumor cells

More Related Videos

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

1.7K
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

16.8K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
650
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.7K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
Canonical Wnt Signaling Pathway02:54

Canonical Wnt Signaling Pathway

The gene encoding the main signaling molecules of the Wnt signaling pathways (the Wnt proteins) was discovered almost four decades ago by Nüsslein-Volhard and Wieschaus. They identified and originally named the gene "wingless" (wg) after a phenotype discovered during their landmark genetic screen in Drosophila for body pattern defects. At around the same time, another researcher named Harold Varmus found that a murine tumor virus activates the mammalian wg homolog, Int-1, which...
8.9K